EU Drug Approval: Sanofi’s Cenrifki (tolebrutinib) has been approved by the European Commission for adults with secondary progressive multiple sclerosis without relapses in the past two years, the first EU authorization aimed at disability progression in nrSPMS; Germany is set to see commercial availability later this year with liver-monitoring risk management. Trade & Pharma Pricing: The U.S. has launched a Section 301 investigation into Germany’s drug pricing policies, alleging “persistent underpayment” for innovative medicines and raising the risk of renewed tariff pressure. Heat & Public Health: A severe European heatwave is driving red alerts, school closures, and emergency measures; France reported heat-related deaths, and Germany issued health warnings as temperatures push dangerous levels. Cardiometabolic Research: A German study links higher vitamin D status in elite male athletes with more favorable atherogenic lipid markers, including lipoprotein(a), adding nuance to long-term cardiovascular risk beyond training. Infectious Disease Diagnostics: New market coverage highlights growth in sepsis diagnostics and microbiology testing, tied to rising infectious threats and faster lab methods. Wellness Nutrition Trend: Reporting on “snacking” suggests people increasingly use snacks as meal replacements and nutrition tools, not just between-meal treats.